Agree. So much could happen in the next 60-90 days to make this go through the roof, or we could be sitting here with the same old back and forth between over Nader. We need more data to take to the FDA, and we need money to keep the lights on and advance the science.
Saltz, I am with you, however, statistically speaking, the word of near zero CTC's don't happen very often.
This is why ONE patient has a large significance, TWO a huge one. Well, 3 and 4 … you get the point.
10 patients with low CTCs and the FDA should be doing in their pants what you so vividly depicted.
As per NP any day now we will have their data. In my opinion (if I can still use this expression) these patients will validate our entrance by the big door of the Oncology world, and for some of us long, the entrance into our banks whistling with full attention of management :-)
If data is not validated we still have something in our hands as the latest approved drug had an improvement in progression free survival (PFS) of near 3 months; apparently patient #1 and #2 are pass this (of course, here I am not using any scientific experiment but they were injected some time ago). Basically, if Lero can extend the life of patients more than 3 months is therapeutically (and economically) viable.
CTC of near 0 (or less than 5) will DEFINITELY extend lives meaningfully (not to mention tumor reduction results).